Los Angeles Capital Management
PASG icon

Los Angeles Capital Management’s Passage Bio PASG Stock Holding History

Los Angeles Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,354
Closed -$270K – 1425
2022
Q1 		$270K Buy
+4,354
New +$359K ﹤0.01% 1279

Other funds holding PASG

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Los Angeles Capital Management's PASG Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Passage Bio (PASG) in Q2 2022, closing a stake of 4,354 shares — an estimated $270K sold.

Los Angeles Capital Management first reported a position in PASG in Q1 2022 and held it in 1 quarter. The position peaked at $270K in Q1 2022. 85 funds tracked by Wall St. Rank hold PASG as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Passage Bio position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 4,354 Passage Bio shares in Q2 2022, an estimated $270K.
  • Los Angeles Capital Management first reported a position in Passage Bio in Q1 2022 and held it in 1 quarter.
  • Los Angeles Capital Management's Passage Bio position peaked at $270K in Q1 2022.
  • 85 funds tracked by Wall St. Rank held Passage Bio as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.